3/23
08:04 am
rlay
Relay Therapeutics (RLAY) had its price target raised by HC Wainwright from $14.00 to $19.00. They now have a "buy" rating on the stock.
Medium
Report
Relay Therapeutics (RLAY) had its price target raised by HC Wainwright from $14.00 to $19.00. They now have a "buy" rating on the stock.
3/19
03:28 pm
rlay
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. [Yahoo! Finance]
Neutral
Report
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. [Yahoo! Finance]
3/17
09:46 am
rlay
Relay Therapeutics (RLAY) had its price target raised by Citizens Jmp from $15.00 to $17.00. They now have a "market outperform" rating on the stock.
Low
Report
Relay Therapeutics (RLAY) had its price target raised by Citizens Jmp from $15.00 to $17.00. They now have a "market outperform" rating on the stock.
3/17
09:19 am
rlay
Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $15.00 to $17.00. They now have an "overweight" rating on the stock.
Low
Report
Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $15.00 to $17.00. They now have an "overweight" rating on the stock.
3/16
09:04 pm
rlay
Relay Therapeutics (RLAY) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Low
Report
Relay Therapeutics (RLAY) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
3/16
07:00 am
rlay
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Medium
Report
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
3/11
12:48 pm
rlay
Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/6
03:51 pm
rlay
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Neutral
Report
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
2/28
07:02 pm
rlay
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest [Yahoo! Finance]
Medium
Report
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest [Yahoo! Finance]
2/27
01:11 pm
rlay
Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $13.00 to $15.00. They now have an "overweight" rating on the stock.
Medium
Report
Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $13.00 to $15.00. They now have an "overweight" rating on the stock.
2/26
04:22 pm
rlay
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones [Yahoo! Finance]
High
Report
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones [Yahoo! Finance]
2/26
04:05 pm
rlay
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
High
Report
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
2/23
04:37 pm
rlay
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March [Yahoo! Finance]
Low
Report
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March [Yahoo! Finance]
2/23
04:05 pm
rlay
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
Low
Report
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
2/19
06:30 pm
rlay
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 [Yahoo! Finance]
Low
Report
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 [Yahoo! Finance]
2/19
05:55 pm
rlay
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
Low
Report
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
2/7
04:11 pm
rlay
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib [Yahoo! Finance]
Low
Report
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib [Yahoo! Finance]
2/4
04:05 pm
rlay
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
2/3
07:52 am
rlay
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer [Yahoo! Finance]
Low
Report
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer [Yahoo! Finance]
2/3
07:00 am
rlay
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Low
Report
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
1/26
07:19 am
rlay
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.
Medium
Report
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.
1/13
04:06 am
rlay
Relay Therapeutics (NASDAQ:RLAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Relay Therapeutics (NASDAQ:RLAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.